ATE273962T1 - 5-phenyl-pyrimidine derivate - Google Patents

5-phenyl-pyrimidine derivate

Info

Publication number
ATE273962T1
ATE273962T1 AT00935104T AT00935104T ATE273962T1 AT E273962 T1 ATE273962 T1 AT E273962T1 AT 00935104 T AT00935104 T AT 00935104T AT 00935104 T AT00935104 T AT 00935104T AT E273962 T1 ATE273962 T1 AT E273962T1
Authority
AT
Austria
Prior art keywords
phenyl
pyrimidine derivatives
pyrimidine
derivatives
Prior art date
Application number
AT00935104T
Other languages
English (en)
Inventor
Michael Boes
Guido Galley
Thierry Godel
Torsten Hoffmann
Walter Hunkeler
Patrick Schnider
Heinz Stadler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE273962T1 publication Critical patent/ATE273962T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT00935104T 1999-05-31 2000-05-24 5-phenyl-pyrimidine derivate ATE273962T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99110482 1999-05-31
PCT/EP2000/004702 WO2000073278A2 (en) 1999-05-31 2000-05-24 5-phenyl-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
ATE273962T1 true ATE273962T1 (de) 2004-09-15

Family

ID=8238270

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935104T ATE273962T1 (de) 1999-05-31 2000-05-24 5-phenyl-pyrimidine derivate

Country Status (36)

Country Link
US (1) US6756380B1 (de)
EP (1) EP1187814B1 (de)
JP (1) JP3590591B2 (de)
KR (1) KR100478369B1 (de)
CN (1) CN1187338C (de)
AR (1) AR024145A1 (de)
AT (1) ATE273962T1 (de)
AU (1) AU769265B2 (de)
BR (1) BR0011097A (de)
CA (1) CA2375670C (de)
CO (1) CO5170529A1 (de)
CZ (1) CZ20014273A3 (de)
DE (1) DE60013127T2 (de)
DK (1) DK1187814T3 (de)
ES (1) ES2225144T3 (de)
GC (1) GC0000338A (de)
HK (1) HK1046411B (de)
HR (1) HRP20010867A2 (de)
HU (1) HU225016B1 (de)
IL (2) IL146519A0 (de)
JO (1) JO2308B1 (de)
MA (1) MA26794A1 (de)
MX (1) MXPA01011704A (de)
MY (1) MY136258A (de)
NO (1) NO321334B1 (de)
NZ (1) NZ515408A (de)
PE (1) PE20010203A1 (de)
PL (1) PL353492A1 (de)
PT (1) PT1187814E (de)
RU (1) RU2244710C2 (de)
SI (1) SI1187814T1 (de)
TR (1) TR200103460T2 (de)
TW (1) TWI263638B (de)
WO (1) WO2000073278A2 (de)
YU (1) YU85001A (de)
ZA (1) ZA200109496B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ514600A0 (en) 2000-01-18 2000-02-10 James Cook University Brain injury treatment
PL362551A1 (en) * 2000-06-13 2004-11-02 Basf Aktiengesellschaft Fungicidal 5-phenyl substituted 2-(cyanoamino) pyrimidines
CA2432642A1 (en) 2000-12-21 2002-08-08 Subhash P. Khanapure Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use
JP2006502107A (ja) 2002-07-02 2006-01-19 エフ．ホフマン−ラ　ロシュ　アーゲー Ｃｃｒ−３レセプターアンタゴニストｉｘとしての２，５−置換ピリミジン誘導体
JP4851337B2 (ja) * 2003-11-10 2012-01-11 シンタ ファーマシューティカルズ コーポレーション ヘテロアリールヒドラゾン化合物
JP2007217282A (ja) * 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
TW200538105A (en) * 2004-04-22 2005-12-01 Procter & Gamble Tri-substituted ureas as cytokine inhibitors
JP2008519850A (ja) * 2004-11-10 2008-06-12 シンタ ファーマシューティカルズ コーポレーション Ｉｌ−１２調節化合物
CA2598762A1 (en) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Tablets with improved drug substance dispersibility
US9013997B2 (en) * 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
SG11201507459YA (en) 2013-03-15 2015-10-29 Epigen Biosciences Inc Heterocyclic compounds useful in the treatment of disease
GB201316600D0 (en) * 2013-09-18 2013-10-30 Redx Pharma Ltd Agricultural chemicals
JP6609253B2 (ja) * 2014-08-06 2019-11-20 キッセイ薬品工業株式会社 シアノチオフェン誘導体
WO2016120355A2 (en) * 2015-01-30 2016-08-04 Basf Se Herbicidal phenylpyrimidines
WO2018015180A1 (en) 2016-07-20 2018-01-25 Basf Se Herbicidal compositions comprising phenylpyrimidines
US20190161451A1 (en) 2016-07-25 2019-05-30 Basf Se Herbicidal pyrimidine compounds
WO2018019552A1 (en) 2016-07-25 2018-02-01 Basf Se Herbicidal pyrimidine compounds
EP3490985B1 (de) 2016-07-26 2020-08-05 Basf Se Herbizide pyrimidinverbindungen
BR112018077223A2 (pt) 2016-07-27 2019-04-09 Basf Se compostos de pirimidina, uso de compostos de pirimidina, composições herbicidas, método para controlar vegetação indesejada e uso das composições herbicidas
EP3490380A1 (de) 2016-07-28 2019-06-05 Basf Se Herbizide pyrimidinverbindungen
CA3064513A1 (en) 2017-06-14 2018-12-20 Basf Se Herbicidal pyrimidine compounds
WO2019121352A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121374A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121408A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2019121373A1 (en) 2017-12-20 2019-06-27 Basf Se Herbicidal pyrimidine compounds
WO2020058062A1 (de) * 2018-09-19 2020-03-26 Bayer Aktiengesellschaft Herbizid wirksame substituierte phenylpyrimidinhydrazide

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940394A (en) * 1972-03-31 1976-02-24 Santilli Arthur A 2-pyrimidinylthio)alkanoic acids, esters, amides and hydrazides
AR208171A1 (es) 1972-09-29 1976-12-09 Ciba Geigy Ag Procedimiento para la obtencion de nuevos derivados del acido cef-3-em-4-carboxilico
IL112134A (en) 1993-12-29 1999-12-22 Merck Sharp & Dohme Substituted morpholine derivatives their preparation and pharmaceutical compositions containing them
JPH11512399A (ja) 1995-09-01 1999-10-26 シグナル ファーマシューティカルズ，インコーポレイテッド ピリミジンカルボキサミドおよび関連化合物ならびに炎症状態を処置するための方法

Also Published As

Publication number Publication date
KR100478369B1 (ko) 2005-03-24
KR20020003399A (ko) 2002-01-12
MY136258A (en) 2008-09-30
HRP20010867A2 (en) 2003-04-30
DK1187814T3 (da) 2004-12-20
TR200103460T2 (tr) 2002-05-21
CA2375670A1 (en) 2000-12-07
HUP0201527A3 (en) 2005-01-28
JO2308B1 (en) 2005-09-12
IL146519A (en) 2006-12-10
CZ20014273A3 (cs) 2002-05-15
WO2000073278A3 (en) 2001-07-05
NO20015701D0 (no) 2001-11-22
NO20015701L (no) 2001-11-22
HK1046411A1 (en) 2003-01-10
CO5170529A1 (es) 2002-06-27
YU85001A (sh) 2004-09-03
JP3590591B2 (ja) 2004-11-17
MXPA01011704A (es) 2002-05-14
CN1187338C (zh) 2005-02-02
US6756380B1 (en) 2004-06-29
DE60013127T2 (de) 2005-09-08
MA26794A1 (fr) 2004-12-20
HUP0201527A2 (en) 2002-08-28
DE60013127D1 (de) 2004-09-23
PL353492A1 (en) 2003-11-17
EP1187814A2 (de) 2002-03-20
TWI263638B (en) 2006-10-11
PE20010203A1 (es) 2001-02-15
IL146519A0 (en) 2002-07-25
HK1046411B (zh) 2005-05-27
NZ515408A (en) 2004-02-27
NO321334B1 (no) 2006-04-24
ES2225144T3 (es) 2005-03-16
JP2003500477A (ja) 2003-01-07
EP1187814B1 (de) 2004-08-18
GC0000338A (en) 2007-03-31
AU769265B2 (en) 2004-01-22
ZA200109496B (en) 2003-02-17
RU2244710C2 (ru) 2005-01-20
AR024145A1 (es) 2002-09-04
BR0011097A (pt) 2002-03-19
WO2000073278A2 (en) 2000-12-07
CA2375670C (en) 2009-09-29
CN1353696A (zh) 2002-06-12
SI1187814T1 (en) 2004-12-31
AU5070800A (en) 2000-12-18
HU225016B1 (en) 2006-05-29
PT1187814E (pt) 2004-10-29

Similar Documents

Publication Publication Date Title
DE60009147D1 (de) Admantan derivate
NO20000885L (no) 4-Fenyl-pyridin-derivater
NO20021077D0 (no) Amino-triazolopyridin-derivater
ATE293104T1 (de) Thiazolylamid-derivate
DE60009747D1 (de) Admantan-derivate
DE60013127D1 (de) 5-phenyl-pyrimidine derivate
EE200100613A (et) 13-metüülerütromütsiini derivaadid
ATE273980T1 (de) 6-phenylpyrrolopyrimidindion derivate
ATE257148T1 (de) Propargyletherderivate
ATE374747T1 (de) Monofluoralkylderivate
DK1154988T3 (da) Mevinolinderivater
DE60025918D1 (de) 4-phenyl-pyrimidine derivate
ATE293592T1 (de) Resorcinderivate
DE60006703D1 (de) 4-hydroxybiphenylhydrazid-derivate
DE69904738D1 (de) 2-phenylpyran-4-one derivate
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
NO20020212L (no) 3-amino-2-benzyl-1-fenyl-propanderivater
DK1178984T3 (da) 1-trifluormethyl-4-hydroxy-7-piperidinylaminomethylchroman-derivater
ATE496034T1 (de) Phtalazinon derivate
DE59909774D1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate
ATE269316T1 (de) 2-phenylpyran-4-on derivate

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1187814

Country of ref document: EP

REN Ceased due to non-payment of the annual fee